Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1983 2
1984 1
1986 3
1987 1
1988 4
1989 2
1990 1
1991 1
1992 1
1993 2
1994 2
1996 1
1999 1
2000 1
2002 1
2004 1
2005 1
2006 3
2008 1
2012 1
2013 1
2014 5
2016 1
2017 6
2018 8
2019 9
2020 9
2021 9
2022 9
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
[Lymphomas in immunocompromised patients].
Plasse F, Bonnin A, Labrousse J, Mottaz P, Carrère F, Augereau PF, Aucher P, Vignon G, Lellouche F. Plasse F, et al. Among authors: augereau pf. Ann Biol Clin (Paris). 2020 Feb 1;78(1):7-16. doi: 10.1684/abc.2020.1521. Ann Biol Clin (Paris). 2020. PMID: 32108583 Free article. Review. French.
Pertuzumab for the treatment of breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: augereau p. Expert Rev Anticancer Ther. 2020 Feb;20(2):85-95. doi: 10.1080/14737140.2019.1596805. Epub 2019 Aug 29. Expert Rev Anticancer Ther. 2020. PMID: 30884986 Review.
Olaparib for the treatment of breast cancer.
Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M. Robert M, et al. Among authors: augereau p. Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21. Expert Opin Investig Drugs. 2017. PMID: 28395540 Review.
Emerging PARP inhibitors for treating breast cancer.
Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M. Robert M, et al. Among authors: augereau p. Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29. Expert Opin Emerg Drugs. 2018. PMID: 30251552 Review.
Diagnostic workup in front of an adult neutropenia.
Bonnin A, Vignon G, Mottaz P, Labrousse J, Carrere F, Augereau PF, Aucher P, Lellouche F. Bonnin A, et al. Among authors: augereau pf. Ann Biol Clin (Paris). 2018 Dec 1;76(6):651-658. doi: 10.1684/abc.2018.1393. Ann Biol Clin (Paris). 2018. PMID: 30543190 Free article. Review. English.
Vinflunine for the treatment of breast cancer.
Gourmelon C, Bourien H, Augereau P, Patsouris A, Frenel JS, Campone M. Gourmelon C, et al. Among authors: augereau p. Expert Opin Pharmacother. 2016 Sep;17(13):1817-23. doi: 10.1080/14656566.2016.1217991. Epub 2016 Aug 10. Expert Opin Pharmacother. 2016. PMID: 27484180 Review.
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Rousseau B, Bieche I, Pasmant E, Hamzaoui N, Leulliot N, Michon L, de Reynies A, Attignon V, Foote MB, Masliah-Planchon J, Svrcek M, Cohen R, Simmet V, Augereau P, Malka D, Hollebecque A, Pouessel D, Gomez-Roca C, Guimbaud R, Bruyas A, Guillet M, Grob JJ, Duluc M, Cousin S, de la Fouchardiere C, Flechon A, Rolland F, Hiret S, Saada-Bouzid E, Bouche O, Andre T, Pannier D, El Hajbi F, Oudard S, Tournigand C, Soria JC, Champiat S, Gerber DG, Stephens D, Lamendola-Essel MF, Maron SB, Diplas BH, Argiles G, Krishnan AR, Tabone-Eglinger S, Ferrari A, Segal NH, Cercek A, Hoog-Labouret N, Legrand F, Simon C, Lamrani-Ghaouti A, Diaz LA, Saintigny P, Chevret S, Marabelle A. Rousseau B, et al. Among authors: augereau p. Cancer Discov. 2022 Jun 2;12(6):1435-1448. doi: 10.1158/2159-8290.CD-21-0521. Cancer Discov. 2022. PMID: 35398880 Free PMC article.
90 results